February 14, 2025

Researchers Evaluate AI-based Smart Glasses and Apps in Patients With Vision Impairment

The tools significantly improved participants' ability to complete text-based tasks.

Conexiant

February 14, 2025

Signs of Immunological Memory in Cases of Occlusive Retinal Vasculitis Following Rechallenge with Faricimab

Real-world case series suggests caution with even mild IOI.

Conexiant

February 14, 2025

Researchers Find Minimal Risk of Adverse Events in Mobile Eye Screening Programs

The most common mild, self-resolving symptoms included eye pain and nervousness about procedures.

Conexiant

February 13, 2025

FDA Approves Extended Label for Avacincaptad Pegol

The new label removes limitations on the duration of dosing.

Conexiant

February 12, 2025

nAMD Patients and Providers Suggest Strategies to Improve Care

Approximately 62% of providers stated in a survey that limited resources and high patient volumes made it difficult to deliver optimal care.

Conexiant

February 06, 2025

AMD and Glaucoma Management Made Easier: The Value of Community Optometrists vs Hospital Care

“Patients perceived primary care-based clinics to be more accessible geographically and being able to negotiate appointment times was also important. Others have found that this can lead to greater engagement with eye care services.”

Conexiant

August 01, 2023

E-insights Into the Latest in Patient Care and Practice Management

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management

September 18, 2024

Assessing the Impact of iRORA Lesions on Retina Sensitivity and Function

A new case study explores the impact of incomplete retinal pigment epithelium and outer retinal atrophy lesions on retinal sensitivity in intermediate age-related macular degeneration, shedding light on potential surrogate markers for retinal dysfunction. (Source: BMJ Open Ophthalmology)

Conexiant

September 30, 2024

Can L-DOPA Protect Against nAMD?

Patients consistently treated with L-DOPA also had lower progression rates from intermediate AMD to nAMD compared to non-treated groups.

Conexiant